Female patients of childbearing potential must agree to use  adequate methods of contraception with their partner starting with the screening visit through  days after the last dose of study therapy.
Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study drug through  days after the last dose of study drug
Female participants of non-childbearing potential must be willing to use adequate contraceptive measures from the Screening Visit (Visit ) through  days after the last dose of study drug; male participants must agree to use an adequate method of contraception starting with the first dose of study drug through  days after the last dose of study drug
Female and male participants of reproductive potential must agree to use contraception starting from the first dose of study medication, throughout the study period, and for up to  days after the last dose of study medication
Male participants of reproductive potential must agree to use an adequate method of contraception starting with the first dose of study medication through  days after the last dose of study medication
Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through  days after the last dose pembrolizumab and  days after the last dose of cetuximab
Male subjects must agree to use one of the methods of contraception specified. This method must be used from the time of the first dose of study medication until  weeks after the last dose of study medication. In addition, male subjects whose partners are or become pregnant must continue to use condoms for  days after stopping study medications.
Male and female subjects of child bearing potential must agree to use an adequate method of contraception for the course of the study through  days after the last dose of study medication
Male participants of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study treatment through  days after the last dose of study treatment.
Male patients must agree to use an adequate method of contraception, or to abstain from heterosexual activity (complete abstinence), starting with the first dose of study drug through  months after the last dose of study therapy
If of childbearing potential as defined in Section .., must be willing to use an adequate method of contraception (see Section ..) from the first dose of study medication through  days after the last dose of study medication
If male, agrees to use an adequate method of contraception starting with the first dose of study drug through  days after the last dose of study drug
POCBP must be willing to use adequate contraception starting with first dose through  days after last dose
Male subjects capable of fathering a child must agree to use an adequate method of contraception starting with the first dose of the study drug through  days after the last dose of the study drug; male subjects will be considered to be capable of fathering a child unless they have azoospermia (whether due to having had a vasectomy or due to an underlying medical condition)
Male subjects agree to use an adequate method of contraception for the course of the study through  days after the last dose of study drug
Male subjects should agree to use an adequate method of contraception starting with the first dose of study medication until  days after the final dose of study medicine; abstinence is acceptable if this is the established and preferred contraceptive method for the subject
Male patients on treatment with TG must agree to use an adequate method of contraception for the duration of the study, and for  days after the last dose of study medication
Males must agree to use an adequate method of contraception during the study and for at least  days after the last dose of study drug or Das
Males must agree to use an adequate method of contraception during the study and for at least  days after the last dose of study drug or LDAC
Male subjects should agree to use an adequate method of contraception during the course of the study and for  days after the last dose of the study drug
Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study medication, throughout the study period, and for up to  days after the last dose of study medication
Male subjects must agree to use an adequate method of contraception starting with the first dose of study medication, while on study, through  days after the last dose of study medication
Male subjects should agree to use an adequate method of contraception starting with the first dose of study drug through  days after the last dose of last study drug
Male participants must agree to use an adequate method of contraception during sexual contact with females of childbearing potential starting with the first dose of study drug through  days after the last dose of study drug
Male participants must agree to use contraception during the treatment period and for at least  days after the last dose of pembrolizumab and up to  days after last dose of chemotherapeutic agents.
Female participants must not be pregnant, not breastfeeding, and must agree to use contraception during the treatment period and for at least  days after the last dose of pembrolizumab and up to  days after the last dose of chemotherapeutic agents.
Male subjects must agree to use an adequate method of contraception starting with the first dose of MK- through  days after the last dose of MK-
Male subjects must agree to the use of male contraception during the treatment period and for at least  days after the last dose of any study drug
Male subjects must agree to the use of male contraception during the treatment period and for at least  days after the last dose of any study drug
Male participants must agree to use adequate contraception for the course of the study starting with the first dose of study medication through  days after the last dose of SOC therapy or  days after the last pembrolizumab dose
Women of childbearing potential and male participants must agree to use adequate contraception starting with the first dose of study therapy through  days after the last dose of study therapy
Male participants of childbearing potential must agree to use adequate contraception from the first dose of study medication, continuing throughout the study, and for up to  days after the last dose of lenalidomide (or  days after the last dose of pembrolizumab).
Male participants of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study drug through  days after the last dose of study drug.
Male participants of childbearing potential should agree to use an adequate method of contraception starting with the first dose of study medication through  days after the last dose of study medication
Male participants of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through  days after the last dose of pembrolizumab or  days after chemotherapy treatment.
Female participants of childbearing potential and male participants must agree to use adequate contraception  days prior to study start and continuing for up to  days after the last dose of pomalidomide (or  days after the last dose of pembrolizumab)
Male participants of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study drug through  days after the last dose of study drug.
If male with a female partner(s) of child-bearing potential, must agree to use adequate contraception starting with the first dose of study medication through  days after the last dose of study medication or through  days after last dose of chemotherapeutic agents.
Male participants of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study drug through  days after the last dose of study drug.
Male subjects must agree to use one of the methods of contraception specified. This method must be used from the time of the first dose of study medication until least  weeks after the last dose of study medication. In addition, male subjects whose partners are or become pregnant while on study medication must continue to use condoms for  days after stopping study medications.
Female and male participants of reproductive potential must agree to use adequate contraception throughout the study period and for up to  days after the last dose of study therapy and for up to  days after the last dose of chemotherapeutic agents or tyrosine kinase inhibitors
Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through  days after the last dose of study drug
Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of trial treatment through  days after the last dose of study medication
Male subjects with female partners of child bearing potential must agree to use one of the methods of contraception specified. This method must be used from the time of the first dose of study medication until  weeks after the last dose of study medication. In addition, male subjects whose partners are or become pregnant on study medication must continue to use condoms for  days after stopping study medication
Male participants must agree to use adequate contraception starting with the first dose through  days after the last dose of study medication
Male participants should agree to use an adequate method of contraception starting with the first dose of study therapy through  days after the last dose of study medication.
Male participants should agree to use an adequate method of contraception starting with the first dose of study therapy through  days after the last dose of pembrolizumab or through  days after the last dose of paclitaxel.
Male participants should agree to use an adequate method of birth control starting with the first dose of study therapy through  days after the last dose of study medication
Male participants must agree to use an adequate method of contraception starting with the first dose of study medication through  days after the last dose of study medication
Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of the study drug through  days after the last dose of the study drug
Male participants must be willing to use an adequate method of contraception starting with the first dose of study medication through  days after the last dose of study treatment
Male participants must be willing to use an adequate method of contraception starting with the first dose of study medication through  days after the last dose of pembrolizumab or  days after the last dose of paclitaxel, docetaxel, or vinflunine
Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through  days after last dose of pembrolizumab or through - days after the last dose of docetaxel, methotrexate or cetuximab, acccording to local standard of care
Male participants of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study medication through  days after the last dose of study medication
Male participants of childbearing potential must agree to use an adequate method of contraception (e.g. abstinence, vasectomy, male condom, etc.) starting with the first dose of study treatment through  days after the last dose of study treatment and up to  days after last dose of cisplatin, and refrain from donating sperm during this period
Female and male participants of childbearing potential must be willing to use an adequate method of contraception, starting with the first dose of study treatment through  days after the last dose of study treatment and up to  days after last dose of chemotherapeutic agents
If of childbearing potential as defined in Section .., must be willing to use an adequate method of contraception (see Section ..) from the first dose of study medication through  days after the last dose of study medication
Females of childbearing potential and male participants must agree to use adequate contraception starting with the first dose of trial treatment through  days after the last dose of study medication
Women of childbearing potential and men must agree to use adequate contraception from  days prior to the first dose of the study drug, during the entire Treatment Period, and for at least  days after the last dose of the study drug
Agrees to use adequate contraception during the study period and for  weeks after the last dose of study medication
Female and male participants of reproductive potential must agree to use adequate contraception throughout the study period and for up to  days after the last dose of study therapy
Willingness to use adequate contraception throughout study and for a period of  days last dose of study drug
Male participants of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study drug through  days (or longer as specified by local institutional guidelines) after the last dose of study drug.